Estimize
Posted - 10/28/24
Wall St is expecting -0.11% YoY revenue growth for $TBPH in Q3, down from 3.69% in Q2 [Reporting 11/12 AMC]
http://www.estimize.com/intro/t
PenkeTrading
Posted - 3 months ago
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Theravance Biopharma Inc. Is that bullish or bearish? $TBPH #TBPH #nasdaq #tradingsignals #technicalanalysis
Thestocktraderhubzee
Posted - 3 months ago
$TBPH Leerink Partners Downgrades Theravance Biopharma to Market Perform, Lowers Price Target to $10
epsguid
Posted - 3 months ago
$TBPH reported a loss of $0.34, consensus was ($0.22) via @eWhispers #epsmiss http://eps.sh/d/tbph
Stock_Titan
Posted - 3 months ago
$TBPH Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
https://www.stocktitan.net/news/TBPH/theravance-biopharma-inc-reports-second-quarter-2024-financial-8l3x7qlm25w9.html
NVDAMillionaire
Posted - 3 months ago
$TBPH Theravance Biopharma, Inc. (NASDAQ:TBPH) – Executing on Key Priorities to Drive Long-Term Value http://beyondspx.com/2024/08/01/theravance-biopharma-inc-nasdaqtbph-executing-on-key-priorities-to-drive-long-term-value/
StockInvest_us
Posted - 07/24/24
Signal alert: $TBPH - Overbought Trend Short (Overvalued) https://stockinvest.us/l/lYOKN8O7Dp
Stock_Titan
Posted - 07/22/24
$TBPH Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024
https://www.stocktitan.net/news/TBPH/theravance-biopharma-to-report-second-quarter-2024-financial-results-vgj9xs6oxgot.html
StockInvest_us
Posted - 4 months ago
Signal alert: $TBPH - Double Bottom https://stockinvest.us/l/8zNd0nvd0F
insiderbuyingselling
Posted - 4 months ago
$TBPH new insider selling: 4000 shares. http://insiderbuyingselling.com/?t=TBPH
falconfly1
Posted - 4 months ago
$EYEN $TBPH and $AQST and $HRMY and $EQ What is new and opportunity in $EYEN? 1 - Insider bought 1.5 million shares in July and paid 1 Million dollars 2 - Vanguard biggest institution in the world bought 5 million dollars for a call option 3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company. 4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 million per quarter. 5 - 8 or 9 August earnings call, and it should be good. 6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.
Stocksrunner
Posted - 4 months ago
$TBPH Wall Street analysts predict a 90.53% upside. Theravance Biopharma closed at $8.66, gaining 1.3% in the past four weeks. Significant upside potential remains based on short-term price targets. https://stocksrunner.com/symbol/TBPH
CristopherKane
Posted - 5 months ago
$TBPH 👇👇
TickerDD_com
Posted - 5 months ago
From 5/23/2024, looking back across 21 Month-Ends for TBPH, Percentage Change of Average Monthly Price had More Positives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $TBPH #TBPH #TBPHStock #TickerDD https://www.youtube.com/watch?v=oFgq_IvsqiE
fda_tracker
Posted - 5 months ago
$TBPH Phase 2 trial w/est Jun completion date NCT04315558: https://www.clinicaltrials.gov/study/NCT04315558 Trial Tracker: https://www.fdatracker.com/trial-tracker/
timfris
Posted - 6 months ago
$TBPH this company exists solely for them execs to get more rich. If not, they would have sold whole company to GSK for $18 and rewarded SH’s. That would have stopped their free shares and salary though.
DonCorleone77
Posted - 6 months ago
$TBPH Theravance Biopharma sees FY24 R&D expenses $30M-$36M Sees FY24 SG&A expenses of $45M-$55M in each case excluding share-based compensation. Sees FY24 share-based compensation expenses $18M-$22M. Expects Non-GAAP net loss in the first half of 2024 and to approach non-GAAP breakeven in the second half of 2024; limited cash burn expected in 2024.
DonCorleone77
Posted - 6 months ago
$TBPH Theravance Biopharma reports Q1 EPS (24c), consensus (25c) Reports Q1 revenue $14.5M, consensus $13.96M. "Building on recent momentum, the Theravance commercial team again delivered a solid quarter of YUPELRI hospital sales execution in the first quarter, setting us on a path to contribute significantly to the product's overall growth in 2024", said Rick E Winningham, CEO. "We remain laser focused on YUPELRI growth and CYPRESS execution and are looking forward to sharing more about our progress and plans for ampreloxetine at a Key Opinion Leader-led virtual investor event scheduled for May 23rd."
epsguid
Posted - 6 months ago
$TBPH reported a loss of $0.24, consensus was ($0.28) via @eWhispers #epsbeat http://eps.sh/d/tbph
Stock_Titan
Posted - 6 months ago
$TBPH Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
https://www.stocktitan.net/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2024-financial-3gd67rwt7o06.html
theflynews
Posted - 6 months ago
Fly Insider: Theravance Bio, Amgen among week's notable insider trades - $TBPH - https://thefly.com/permalinks/entry.php/TBPHid3911411
StockInvest_us
Posted - 6 months ago
Signal alert: $TBPH - Possible Runner https://stockinvest.us/l/bF19xIdAcO
Aigner_Andreas
Posted - 04/30/24
TD BUY $TBPH at 8.44, Supp 8.44 Resis 9.92 R18 HiLo 7% T1Y 11 hold 2.7 DIV N/A #Theravance #stocks #trading #finance #market
Stock_Titan
Posted - 04/29/24
$TBPH Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
https://www.stocktitan.net/news/TBPH/theravance-biopharma-to-report-first-quarter-2024-financial-results-6fe62gbew5m4.html
Stock_Titan
Posted - 7 months ago
$TBPH Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
https://www.stocktitan.net/news/TBPH/theravance-biopharma-inc-to-host-virtual-key-opinion-leader-kol-zlgyyg6o92l1.html
Aigner_Andreas
Posted - 02/28/24
TD SELL $TBPH at 9.69, Supp 8.22 Resis 9.69 R18 HiLo 40% T1Y 11 hold 2.7 DIV N/A #Theravance #stocks #trading #finance #market
epsguid
Posted - 02/26/24
$TBPH reported a loss of $0.17, consensus was ($0.15) via @eWhispers #epsmiss http://eps.sh/d/tbph
Ninja_Tradez
Posted - 02/26/24
$SSKN $NRXP $IOBT $TBPH Never Miss any alert 🚨Check Discord Link 🔗 on bio
Stock_Titan
Posted - 02/26/24
$TBPH Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
https://www.stocktitan.net/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2023-bu2w6bo7hyof.html
